{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:20:38Z","timestamp":1787314838108,"version":"build-2736575974"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Dutch Duchenne Parent Project (NL_DPP) 2015"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.phrs.2019.104260","type":"journal-article","created":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T11:57:08Z","timestamp":1556884628000},"page":"104260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Proof-of-concept validation of the mechanism of action of Src tyrosine kinase inhibitors in dystrophic mdx mouse muscle: in vivo and in vitro studies"],"prefix":"10.1016","volume":"145","author":[{"given":"F.","family":"Sanarica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mantuano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cozzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.F.","family":"Capogrosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Giustino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cutrignelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Cappellari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"De Bellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Denora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.M.","family":"Camerino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2019.104260_bib0005","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0165-6147(00)01770-3","article-title":"Molecular pathophysiology and targeted therapeutics for muscular dystrophy","volume":"22","author":"Hoffman","year":"2001","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2019.104260_bib0010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.phrs.2019.104260_bib0015","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.ymthe.2018.03.018","article-title":"Functional rescue of dystrophin deficiency in mice caused by frameshift mutations using campylobacter jejuni Cas9","volume":"26","author":"Koo","year":"2018","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.phrs.2019.104260_bib0020","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"Aartsma-Rus","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.phrs.2019.104260_bib0025","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/mt.2011.59","article-title":"Current status of pharmaceutical and genetic therapeutic approaches to treat DMD","volume":"19","author":"Pichavant","year":"2011","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.phrs.2019.104260_bib0030","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.nmd.2012.05.016","article-title":"The inside and out of dystroglycan post-translational modification","volume":"22","author":"Moore","year":"2012","journal-title":"Neuromuscul. Disord. NMD"},{"key":"10.1016\/j.phrs.2019.104260_bib0035","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0898-6568(01)00188-7","article-title":"The interaction of dystrophin with beta-dystroglycan is regulated by tyrosine phosphorylation","volume":"13","author":"Ilsley","year":"2001","journal-title":"Cell. Signal."},{"key":"10.1016\/j.phrs.2019.104260_bib0040","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/hmg\/ddr265","article-title":"Chronic AMPK activation evokes the slow, oxidative myogenic program and triggers beneficial adaptations in mdx mouse skeletal muscle","volume":"20","author":"Ljubicic","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.phrs.2019.104260_bib0045","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bcp.2018.04.022","article-title":"Effect of a long-term treatment with metformin in dystrophic mdx mice: A reconsideration of its potential clinical interest in Duchenne muscular dystrophy","volume":"154","author":"Mantuano","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phrs.2019.104260_bib0050","doi-asserted-by":"crossref","first-page":"7110","DOI":"10.1021\/bi0271289","article-title":"Localization of phospho-beta-dystroglycan (pY892) to an intracellular vesicular compartment in cultured cells and skeletal muscle fibers in vivo","volume":"42","author":"Sotgia","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2019.104260_bib0055","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1038\/ncomms5425","article-title":"Src-dependent impairment of autophagy by oxidative stress in a mouse model of Duchenne muscular dystrophy","volume":"5","author":"Pal","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2019.104260_bib0060","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1093\/hmg\/ddu287","article-title":"Gene expression in mdx mouse muscle in relation to age and exercise: aberrant mechanical-metabolic coupling and implications for pre-clinical studies in Duchenne muscular dystrophy","volume":"23","author":"Camerino","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.phrs.2019.104260_bib0065","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1242\/jcs.032003","article-title":"TRPC1 binds to caveolin-3 and is regulated by Src kinase - role in Duchenne muscular dystrophy","volume":"121","author":"Gerv\u00e1sio","year":"2008","journal-title":"J. Cell. Sci."},{"key":"10.1016\/j.phrs.2019.104260_bib0070","first-page":"1311","article-title":"Multiple pathological events in exercised dystrophic mdx mice are targeted by pentoxifylline: outcome of a large array of in vivo and ex vivo tests","volume":"106","author":"Burdi","year":"2009","journal-title":"J. Appl. Physiol. Bethesda Md 1985"},{"key":"10.1016\/j.phrs.2019.104260_bib0075","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.1097\/00002060-200211001-00018","article-title":"Oxidative stress and the pathogenesis of muscular dystrophies","volume":"81","author":"Rando","year":"2002","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"10.1016\/j.phrs.2019.104260_bib0080","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jprot.2017.09.009","article-title":"Proteome analysis in dystrophic mdx mouse muscle reveals a drastic alteration of key metabolic and contractile proteins after chronic exercise and the potential modulation by anti-oxidant compounds","volume":"170","author":"Gamberi","year":"2018","journal-title":"J. Proteomics"},{"key":"10.1016\/j.phrs.2019.104260_bib0085","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.3390\/ijms14023683","article-title":"NADPH oxidase biology and the regulation of tyrosine kinase receptor signaling and cancer drug cytotoxicity","volume":"14","author":"Paletta-Silva","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2019.104260_bib0090","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.freeradbiomed.2010.04.025","article-title":"Src redox regulation: again in the front line","volume":"49","author":"Giannoni","year":"2010","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.phrs.2019.104260_bib0095","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1093\/hmg\/dds293","article-title":"Preventing phosphorylation of dystroglycan ameliorates the dystrophic phenotype in mdx mouse","volume":"21","author":"Miller","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.phrs.2019.104260_bib0100","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.2353\/ajpath.2010.090468","article-title":"Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies","volume":"176","author":"Gazzerro","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.phrs.2019.104260_bib0105","doi-asserted-by":"crossref","first-page":"C577","DOI":"10.1152\/ajpcell.00434.2005","article-title":"Pharmacological rescue of the dystrophin-glycoprotein complex in Duchenne and Becker skeletal muscle explants by proteasome inhibitor treatment","volume":"290","author":"Assereto","year":"2006","journal-title":"Am. J. Physiol. Cell. Physiol."},{"key":"10.1016\/j.phrs.2019.104260_bib0110","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/nm.2247","article-title":"Autophagy is defective in collagen VI muscular dystrophies, and its reactivation rescues myofiber degeneration","volume":"16","author":"Grumati","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2019.104260_bib0115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2015.01.003","article-title":"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors","volume":"94","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104260_bib0120","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/hmg\/ddv469","article-title":"Dasatinib as a treatment for Duchenne muscular dystrophy","volume":"25","author":"Lipscomb","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.phrs.2019.104260_bib0125","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.nbd.2008.07.009","article-title":"Gentamicin treatment in exercised mdx mice: identification of dystrophin-sensitive pathways and evaluation of efficacy in work-loaded dystrophic muscle","volume":"32","author":"De Luca","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.phrs.2019.104260_bib0130","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0002-9440(10)62270-5","article-title":"A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice","volume":"166","author":"De Luca","year":"2005","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.phrs.2019.104260_bib0135","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O\u2019Hare","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2019.104260_bib0140","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.2337\/db12-1010","article-title":"Inhibition of Src kinase blocks high glucose-induced EGFR transactivation and collagen synthesis in mesangial cells and prevents diabetic nephropathy in mice","volume":"62","author":"Taniguchi","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2019.104260_bib0145","first-page":"1025","article-title":"Ryanodine channel complex stabilizer compound S48168\/ARM210 as a disease modifier in dystrophin-deficient mdx mice: proof-of-concept study and independent validation of efficacy","volume":"32","author":"Capogrosso","year":"2018","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"10.1016\/j.phrs.2019.104260_bib0150","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.phrs.2016.02.016","article-title":"Assessment of resveratrol, apocynin and taurine on mechanical-metabolic uncoupling and oxidative stress in a mouse model of duchenne muscular dystrophy: A comparison with the gold standard, \u03b1-methyl prednisolone","volume":"106","author":"Capogrosso","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104260_bib0155","first-page":"828","article-title":"Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points","volume":"122","author":"Capogrosso","year":"2017","journal-title":"J. Appl. Physiol. Bethesda Md 1985"},{"key":"10.1016\/j.phrs.2019.104260_bib0160","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/labinvest.2013.46","article-title":"Effects of prednisolone on the dystrophin-associated proteins in the blood-brain barrier and skeletal muscle of dystrophic mdx mice","volume":"93","author":"Tamma","year":"2013","journal-title":"Lab. Investig. J. Tech. Methods Pathol."},{"key":"10.1016\/j.phrs.2019.104260_bib0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129686","article-title":"Effects of nandrolone in the counteraction of skeletal muscle atrophy in a mouse model of muscle disuse: molecular biology and functional evaluation","volume":"10","author":"Camerino","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.phrs.2019.104260_bib0170","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1373\/clinchem.2008.112797","article-title":"The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments","volume":"55","author":"Bustin","year":"2009","journal-title":"Clin. Chem."},{"key":"10.1016\/j.phrs.2019.104260_bib0175","doi-asserted-by":"crossref","first-page":"C1090","DOI":"10.1152\/ajpcell.00450.2001","article-title":"Fast-twitch skeletal muscles of dystrophic mouse pups are resistant to injury from acute mechanical stress","volume":"283","author":"Grange","year":"2002","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.phrs.2019.104260_bib0180","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1387-2656(05)11004-7","article-title":"Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction","volume":"11","author":"Berridge","year":"2005","journal-title":"Biotechnol. Annu. Rev."},{"key":"10.1016\/j.phrs.2019.104260_bib0185","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1293\/tox.26.29","article-title":"Change trends of organ weight background data in sprague dawley rats at different ages","volume":"26","author":"Piao","year":"2013","journal-title":"J. Toxicol. Pathol."},{"key":"10.1016\/j.phrs.2019.104260_bib0190","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.nmd.2011.05.011","article-title":"Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD)","volume":"21","author":"Nadarajah","year":"2011","journal-title":"Neuromuscul. Disord. NMD"},{"key":"10.1016\/j.phrs.2019.104260_bib0195","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1517\/17425255.2010.506873","article-title":"Metabolism considerations for kinase inhibitors in cancer treatment","volume":"6","author":"Duckett","year":"2010","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.phrs.2019.104260_bib0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117215","article-title":"Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting","volume":"10","author":"Rao","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.phrs.2019.104260_bib0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019189","article-title":"Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse","volume":"6","author":"Tinsley","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.phrs.2019.104260_bib0210","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1083\/jcb.200604179","article-title":"Plectin 1f scaffolding at the sarcolemma of dystrophic (mdx) muscle fibers through multiple interactions with beta-dystroglycan","volume":"176","author":"Rezniczek","year":"2007","journal-title":"J. Cell. Biol."},{"key":"10.1016\/j.phrs.2019.104260_bib0215","doi-asserted-by":"crossref","first-page":"6301","DOI":"10.1074\/jbc.M110.178988","article-title":"A dystroglycan\/plectin scaffold mediates mechanical pathway bifurcation in lung epithelial cells","volume":"286","author":"Takawira","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2019.104260_bib0220","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1165\/rcmb.2007-0432OC","article-title":"Stretch-induced activation of AMP kinase in the lung requires dystroglycan","volume":"39","author":"Budinger","year":"2008","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.phrs.2019.104260_bib0225","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.matbio.2007.11.003","article-title":"Src kinase regulates metalloproteinase-9 secretion induced by type IV collagen in MCF-7 human breast cancer cells","volume":"27","author":"Cortes-Reynosa","year":"2008","journal-title":"Matrix Biol. J. Int. Soc. Matrix Biol."},{"key":"10.1016\/j.phrs.2019.104260_bib0230","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s13256-015-0674-9","article-title":"Inclusion body myositis in a patient with chronic myeloid leukemia treated with dasatinib: a case report","volume":"9","author":"AlJohani","year":"2015","journal-title":"J. Med. Case Reports"},{"key":"10.1016\/j.phrs.2019.104260_bib0235","first-page":"1","article-title":"An unexpected and devastating adverse event of dasatinib: Rhabdomyolysis","volume":"5","author":"Uz","year":"2016","journal-title":"Leuk. Res. Rep."},{"key":"10.1016\/j.phrs.2019.104260_bib0240","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.3892\/ijo.2016.3678","article-title":"Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs","volume":"49","author":"Puvanenthiran","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.phrs.2019.104260_bib0245","doi-asserted-by":"crossref","first-page":"918","DOI":"10.2174\/138161213804547295","article-title":"Synergistic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibitors","volume":"19","author":"Porcelli","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2019.104260_bib0250","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3389\/fphys.2014.00476","article-title":"The large conductance Ca(2+) -activated K(+) (BKCa) channel regulates cell proliferation in SH-SY5Y neuroblastoma cells by activating the staurosporine-sensitive protein kinases","volume":"5","author":"Curci","year":"2014","journal-title":"Front. Physiol."},{"key":"10.1016\/j.phrs.2019.104260_bib0255","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3389\/fphar.2017.00907","article-title":"Dual action of mexiletine and its pyrroline derivatives as skeletal muscle sodium channel blockers and anti-oxidant compounds: toward novel therapeutic potential","volume":"8","author":"De Bellis","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2019.104260_bib0260","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20030591","article-title":"Dasatinib\/HP-\u03b2-CD inclusion complex based aqueous formulation as a promising tool for the treatment of paediatric neuromuscular disorders","volume":"20","author":"Cutrignelli","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2019.104260_bib0265","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1124\/jpet.111.185835","article-title":"Structural nucleotide analogs are potent activators\/inhibitors of pancreatic \u03b2 cell KATP channels: an emerging mechanism supporting their use as antidiabetic drugs","volume":"340","author":"Tricarico","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2019.104260_bib0270","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/cmdc.201100600","article-title":"Identification of selective inhibitors of the potassium channel Kv1.1-1.2((3)) by high-throughput virtual screening and automated patch clamp","volume":"7","author":"Wacker","year":"2012","journal-title":"ChemMedChem"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819300398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819300398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T06:21:25Z","timestamp":1567146085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819300398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":54,"alternative-id":["S1043661819300398"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104260","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proof-of-concept validation of the mechanism of action of Src tyrosine kinase inhibitors in dystrophic mdx mouse muscle: in vivo and in vitro studies","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104260","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104260"}}